This inventor holds 1 USPTO granted patent. Top assignee: Pacific Biotech, Inc.. Active years: 1993.
Company Filing History:
Years Active: 1993
Title: **Sinfu Tzeng: Innovator in Immunoassay Technology**
Introduction
Sinfu Tzeng is an esteemed inventor based in San Francisco, California, recognized for his significant contributions to the field of immunoassay devices. With a focus on creating efficient and cost-effective solutions, Tzeng has distinguished himself in the biotechnology sector.
Latest Patents
Sinfu Tzeng holds a patent for a solid-phase immunoassay device and method of making the same. This invention addresses a critical need for an immunoassay device with universal applicability, promoting inventory reduction and simplifying the manufacturing process. The patent describes a container designed for holding materials used in immunoassays, featuring a housing with an interior, exterior, and a top that has multiple apertures. A thin web of opaque material is applied over the top, covering at least one but not all of the apertures, enhancing the device's versatility and functionality.
Career Highlights
Currently, Sinfu Tzeng is associated with Pacific Biotech, Inc., where he continues to develop innovative technologies in the biotechnology field. His work is pivotal in pushing the boundaries of what is possible in immunoassay applications, contributing significantly to advancements in medical diagnostics.
Collaborations
In his professional journey, Sinfu Tzeng has collaborated with talented colleagues, including Eugene Fan and Fon-Chiu M Chen. Their combined expertise fosters an environment of innovation and progress within their projects, further enhancing the impact of their work at Pacific Biotech, Inc.
Conclusion
Sinfu Tzeng’s contributions to the field of immunoassay technology are commendable. His innovative patent reflects a commitment to improving medical diagnostics through effective and economical solutions. As he continues his work at Pacific Biotech, Inc., the potential for future advancements undoubtedly remains promising.